Werewolf Therapeutics to Participate in the BIO International Convention
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
Cancer
Werewolf Therapeutics to Participate in the BIO International Convention
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
Aayush Wellness Bridging Ancient Ayurvedic Wisdom with Modern Wellness offering Aayush Herbal Masala – A Natural Alternative
NEW DELHI, India, June 12, 2025 (GLOBE NEWSWIRE) -- Aayush Wellness Limited, a trailblazer in India's preventive healthcare sector, seamlessly...
Aayush Wellness Bridging Ancient Ayurvedic Wisdom with Modern Wellness offering Aayush Herbal Masala – A Natural Alternative
NEW DELHI, India, June 12, 2025 (GLOBE NEWSWIRE) -- Aayush Wellness Limited, a trailblazer in India's preventive healthcare sector, seamlessly...
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with...
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with...
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed...
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed...
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in...
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in...
Medicus Pharma Ltd. to Present at 2025 Bio International Convention
Company Executive Chairman & CEO to Provide Corporate Updates on June 17th 2025Philadelphia, Pennsylvania--(Newsfile Corp. - June 12, 2025) -...
Outcomes4Me Acquires Germany’s Mika Health App to Accelerate AI-Driven Patient Empowerment Globally
Mika's cancer app is a certified medical device clinically proven to help cancer patients cope with both the physical and...
Bio Ascend, a Vaniam Group Company, Hosts Third Cohort of Next Wave Forum for Young Investigators in Thoracic Oncology
Twenty promising early-career clinical investigators join a year-long mentorship and training program led by renowned international leaders, aimed at shaping...
“STRONGER TOGETHER”: SWITZERLAND CHAMPIONS INTERNATIONAL PARTNERSHIPS AS KEY TO ACCELERATED INNOVATION”, ONCE AGAIN SWITZERLAND IS SHOWCASING ITS BIOTECH EXCELLENCE AT BIO INTERNATIONAL IN BOSTON 16-19 JUNE, 2025
Swiss biotech excellence returns to BIO 2025 in Boston, where Switzerland Global Enterprise presents 45 cutting-edge Swiss companies at the...
Europe’s Rising Tech & AI Hub: 6 Startups from Brno You Can’t Miss
BRNO, Czech Republic, June 11, 2025 /PRNewswire/ -- In the heart of Europe, the Brno region is emerging as a...
Lisata Therapeutics to Present at the 2025 BIO International Convention
BASKING RIDGE, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Artelo Biosciences Announces Reverse Stock Split
Shares Expected to Begin Trading on a Split-Adjusted Basis on June 13, 2025SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE)...
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25...
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline...
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing
Facility provides additional funding for next steps of the Company’s growth, including the expected launch of bezuclastinib in 2026 On...